China Pushes Vaccines as Retreat From ‘Zero-COVID’ Turns Messy

BEIJING/SHANGHAI (Reuters) – China raced to vaccinate its most vulnerable people on Thursday in anticipation of waves of COVID-19 infections, with some analysts expecting the death toll to soar after it eased strict controls that had kept the pandemic at bay for three years.

The push comes as the World Health Organisation also raised concerns that China’s 1.4 billion population was not adequately vaccinated and the United States offered help in dealing with a surge in infections.

Beijing last Wednesday began dismantling its tough ‘zero-COVID’ controls, dropping testing requirements and easing quarantine rules that had caused anxiety for tens of millions and battered the world’s second largest economy.

The pivot away from President Xi Jinping’s signature “zero-COVID” policy followed unprecedented widespread protests against it. But, WHO emergencies director Mike Ryan said infections were exploding in China well before the government’s decision to phase out its stringent regime.

“There’s a narrative at the moment that China lifted the restrictions and all of a sudden the disease is out of control,” Ryan told a briefing in Geneva.

“The disease was spreading intensively because I believe the control measures in themselves were not stopping the disease.”

Chinese foreign ministry spokesperson Wang Wenbin said on Thursday China has “institutional advantages” to fight COVID.

“We will certainly be able to smoothly get through the peak of the epidemic,” he told a regular news briefing in response to White House national security spokesperson John Kirby saying that the United States was ready to help if China requested it.

There are increasing signs of chaos during China’s change of tack – including long queues outside fever clinics, runs on medicines and panic buying across the country.

On Thursday night, China’s state asset regulator urged state-backed big drugmakers to ensure supplies of COVID-related medicines.

The companies include China Resources, China General Technology and Sinopharm, which own businesses that produce drugs that could ease coronavirus symptoms.

One video posted online on Wednesday showed several people in thick winter clothes hooked up to intravenous drips as they sat on stools on the street outside a clinic in central Hubei province. Reuters verified the location of the video.

The COVID scare in China also led people in Hong Kong, Macau and in some neighbourhoods in Australia to go in search for fever medicines and test kits for family and friends on the mainland.

For all its efforts to quell the virus since it erupted in the central city of Wuhan in late 2019, China may now pay a price for shielding a population that lacks “herd immunity” and has low vaccination rates among the elderly, analysts said.

“Authorities have let cases in Beijing and other cities spread to the point where resuming restrictions, testing and tracing would be largely ineffective in bringing outbreaks under control,” analysts at Eurasia Group said in a note on Thursday.

“Upward of 1 million people could die from COVID in the coming months.”

Other experts have put the potential toll at more than 2 million. China has reported just 5,235 COVID-related deaths so far, extremely low by global standards.

China’s stock markets and its currency fell on Thursday on concerns of the virus spread.

China reported 2,000 new symptomatic COVID-19 infections for Dec. 14 compared with 2,291 a day. The official figures, however, have become less reliable as testing has dropped. It also stopped reporting asymptomatic figures on Wednesday.

CONCERN FOR ELDERLY

China, which has said around 90% of its population is vaccinated against COVID, has now decided to roll out the second booster shot for high-risk groups and elderly people over 60 years of age.

National Health Commission spokesperson Mi Feng said on Wednesday it was necessary to accelerate the promotion of vaccinations, according to comments reported by state media.

The latest official data shows China administered 1.43 million COVID shots on Tuesday, well above rates in November of around 100,000-200,000 doses a day. In total, it has administered 3.45 billion shots.

But one Shanghai care home said on Wednesday a number of its residents have not yet been vaccinated and considering their underlying medical condition, it has barred visitors and non-essential deliveries while stockpiling medicines, tests kits and protective gear.

“We are racking our brains on how to ensure the safety of your grandparents,” the Yuepu Tianyi Nursing Home wrote in a letter posted on its official WeChat account page.

Beijing has been largely resistant to western vaccines and treatments, having relied on locally-made shots. Pfizer’s oral COVID-19 treatment Paxlovid is one of the few foreign ones it has approved.

The treatment, however, has only been available in hospitals for high-risk patients, but signs have appeared in recent days that it may soon be made more widely available.

China Meheco Group Co Ltd’s stock jumped after it announced a deal to import the U.S. drugmaker’s treatment on Wednesday.

ECONOMIC CONFERENCE

As the virus spreads, President Xi, his ruling Politburo and senior government officials began a two-day meeting to plot a recovery for China’s battered economy, according to sources with knowledge of the matter.

China’s economy lost more steam in November as factory output growth slowed and retail sales extended declines, both missing forecasts and clocking their worst readings since May, data on Thursday showed.

Economists estimate that China’s growth has slowed to around 3% this year, marking one of China’s worst performances in almost half a century.

(Reporting by Albee Zhang, Liz Lee and Bernard Orr in Beijing, Brenda Goh in Shanghai and Stella Qiu in Sydney; Additional reporting by Ella Cao in Beijing;Writing by John Geddie and Greg Torode;Editing by Simon Cameron-Moore and Arun Koyyur)

Source: Read Full Article